The Supreme Court Just Changed Your Roundup Case — Here Is What It Means for You
You used Roundup for years. Maybe decades. You developed non-Hodgkin’s lymphoma. A jury in Missouri looked at the evidence and awarded more than a million dollars to a man whose story sounds like yours — and then the United States Supreme Court took that verdict away. If you are reading this at 2 a.m. with a folder of medical bills and a phone full of voicemails from a lawyer who has not called back since the news broke, you need to know three things right now, before anything else.
First: the ruling does not say Roundup is safe. The Court said so explicitly. It answered one legal question — whether a state-law failure-to-warn claim can go forward when the warning sought is not part of the label approved by the EPA. It did not decide whether glyphosate causes cancer. It did not exonerate Monsanto. It drew a line around one specific legal theory.
Second: your case is not automatically dead. The theory that the Supreme Court barred — failure to warn based on a label warning the EPA did not require — was the theory that produced the million-dollar Missouri verdict, and that verdict has been reversed. But there are other theories. Design defect, negligence, and fraud claims challenge different things — the product’s formulation, the company’s conduct, the alleged suppression of scientific data — and the Supreme Court’s ruling did not directly address them. Whether your specific case survives depends on facts unique to you, and on how your lawyer pleads it.
Third: the clock is running, and the proof is dying. Medical records, Roundup purchase history, internal corporate documents, expert causation reports — every piece of evidence in a Roundup case has a shelf life, and some of it is shorter than you think. We are Attorney911, The Manginello Law Firm — a trial firm that takes Missouri cases, working with local counsel where required. We handle toxic tort and product liability claims, and we are going to tell you, straight and in plain English, exactly what this ruling does, what it does not do, and what you should do next.
Can I Still Sue Monsanto After the Supreme Court’s Roundup Ruling?
Yes — but the primary legal pathway has been significantly narrowed, and the landscape has shifted decisively in the defense’s favor. The 7-2 decision bars state-law failure-to-warn claims when the warning sought would require a pesticide label different from the one the EPA approved. Because EPA approved Roundup’s label without a cancer warning, and because Monsanto was legally required to use that EPA-approved label, the Court held that Missouri law could not require a different warning through a tort claim.
But the ruling is a scalpel, not a sledgehammer — at least in theory. It cut away the failure-to-warn theory. It did not cut away every theory. A design defect claim that challenges Roundup’s formulation itself, rather than its label, was not directly addressed. A negligence claim based on Monsanto’s conduct in researching, testing, and marketing the product — to the extent it is not premised on a duty to add warnings to the EPA-approved label — was not directly addressed. A fraud claim based on the alleged suppression or manipulation of cancer risk data, independent of labeling requirements, was not directly addressed.
Whether those alternative theories can carry your case depends on your specific facts, the strength of your evidence, and how skillfully your lawyer separates the preempted labeling claims from the potentially surviving non-labeling claims. That triage is the single most important thing that happens in a Roundup case right now, and it should happen immediately — not after the defense files a motion to dismiss that tries to sweep everything into the preemption bucket.
The Missouri man whose case reached the Supreme Court used Roundup products for approximately 20 years. A Missouri jury awarded him more than $1 million on the failure-to-warn theory. The Missouri Court of Appeals allowed his claim to proceed. Several other state and federal courts had similarly rejected Monsanto’s preemption argument before the Supreme Court took up the case. The Supreme Court has now reversed that consensus — but only on the failure-to-warn theory, and only where the warning sought differs from the EPA-approved label.
What FIFRA Preemption Actually Bars — and What It Does Not
FIFRA — the Federal Insecticide, Fungicide, and Rodenticide Act — is the federal law that gives the EPA authority over pesticide registration and labeling. It is the reason every pesticide bottle on a hardware store shelf carries a specific, EPA-approved label with specific warnings, usage instructions, and safety statements. A manufacturer cannot legally sell a pesticide with a label the EPA has not approved, and once the EPA approves a label, the manufacturer is legally required to use that exact label unless the EPA approves or requires a change.
FIFRA also contains a provision aimed at label uniformity — a preemption clause that bars states from imposing pesticide labeling or packaging requirements that conflict with the federal scheme:
FIFRA bars states from imposing pesticide labeling or packaging requirements that are “in addition to or different from” requirements under federal law.
The Supreme Court’s majority, in an opinion written by Justice Kavanaugh and joined by six other Justices, held that a state-law failure-to-warn verdict functions as exactly that kind of prohibited state labeling requirement. When a jury in Missouri says Monsanto should have added a cancer warning to Roundup’s label, that verdict — even though it comes through a tort claim rather than a statute — effectively imposes a state labeling requirement different from the label the EPA approved. And FIFRA says states cannot do that.
The majority’s reasoning is mechanical but powerful: after the EPA approves a pesticide label, the manufacturer is legally required to use that label. The EPA approved Roundup’s label without a cancer warning. The EPA has repeatedly reviewed glyphosate and repeatedly concluded that it is not likely to cause cancer. If Missouri tort law could require Monsanto to add a cancer warning that the EPA did not require, Monsanto would be caught between a federal duty to use the EPA-approved label and a state duty to use a different one — and FIFRA’s uniform-labeling rule says the federal duty wins.
What this bars: Any state-law claim that seeks to hold Monsanto liable for failing to add a cancer warning to Roundup’s label, where that warning is not part of the EPA-approved label. The $1 million-plus Missouri verdict was on exactly this theory, and it has been reversed.
What this does not bar — at least not directly: Claims that do not require a label change. A design defect claim that says Roundup’s formulation itself was unreasonably dangerous — not that the label was inadequate, but that the product was dangerous by design — challenges the product, not the label. A negligence claim that says Monsanto’s conduct in researching and marketing the product was unreasonable — independent of any duty to change the label — challenges the company’s conduct, not the label. A fraud claim that says Monsanto suppressed or manipulated scientific data about cancer risk — independent of what the label says — challenges the company’s honesty, not the label.
The defense will argue that every one of these alternative theories is just failure-to-warn in disguise — that any claim premised on cancer risk necessarily implies that the label should have carried a warning, and is therefore preempted. That argument is not frivolous. But it is not what the Supreme Court held, and it is the fight that will define the next phase of Roundup litigation.
The Four Legal Theories and Which Ones Survived
Missouri product liability law recognizes three traditional theories of recovery — manufacturing defect, design defect, and failure to warn — plus common-law negligence and fraud. Here is where each stands after the ruling.
1. Failure to Warn — FIFRA-PREEMPTED (largely barred). This was the theory that produced the $1 million-plus Missouri verdict, now reversed. The claim: Monsanto should have included a cancer warning on Roundup’s label. The Supreme Court held that this claim imposes a state labeling requirement different from the EPA-approved label, which FIFRA bars. For cases where the only theory is failure to warn based on a label warning the EPA did not require, this ruling is close to a death sentence. The defense will move to dismiss, and the majority’s reasoning gives them strong ammunition.
2. Design Defect — POTENTIALLY VIABLE (not directly addressed). This theory does not say the label was wrong. It says the product itself was unreasonably dangerous — that Roundup’s glyphosate-based formulation was defective by design, and that a safer alternative design existed or was feasible. The remedy for a design defect is not a label change. It is changing the product. The Supreme Court’s preemption analysis — which turns on the conflict between a state labeling requirement and the EPA-approved label — does not map neatly onto a claim that challenges the formulation rather than the label. The defense will argue that any design defect claim premised on cancer risk necessarily implies the need for a warning, making it preempted in substance if not in form. That is the fight. But the theory itself was not addressed by the ruling, and Missouri law recognizes it as distinct from failure to warn.
3. Negligence — POTENTIALLY VIABLE (to the extent independent of labeling). This theory challenges Monsanto’s conduct — how it researched, tested, marketed, and promoted Roundup. A negligence claim that says Monsanto failed to conduct adequate safety testing, or marketed the product in a way that encouraged unsafe use, or ignored internal research showing cancer risk, is a claim about the company’s behavior, not about what the label said. To the extent the negligence claim is premised on a duty to add warnings to the EPA-approved label, it is likely preempted. To the extent it is premised on independent conduct — research, testing, marketing, promotion — it may survive.
4. Fraud / Misrepresentation — POTENTIALLY VIABLE (if independent of labeling). This theory says Monsanto suppressed, manipulated, or misrepresented scientific data about glyphosate’s cancer risk — not that the label was wrong, but that the company lied about the science. If supported by internal corporate documents showing knowledge of cancer risk and deliberate suppression of that information, a fraud claim challenges the company’s honesty rather than its label. The defense will argue that any fraud claim that ultimately seeks a warning is preempted. But if the fraud is about the scientific record itself — about what the company told regulators, scientists, and the public — it may be independent enough to survive.
Here is what the generalist misses: the lawyer who reads this ruling and tells the client “your case is over” has stopped at the headline. The lawyer who reads the ruling carefully — who sees that the majority’s analysis turns on the specific mechanism of a labeling requirement conflicting with an EPA-approved label — starts building a case around what the company knew, what the company did with that knowledge, and whether the product itself was dangerous by design, not just by label. That pivot, from a label claim to a product claim, is the difference between a dismissed case and one that survives.
Monsanto, Bayer, and the Corporate Structure Behind Roundup
Monsanto Company manufactured and distributed Roundup for decades from its headquarters in St. Louis, Missouri — a company founded in Missouri in 1901 and rooted there for over a century. That Missouri presence is precisely why Missouri courts became a significant venue for Roundup litigation. The case that reached the Supreme Court started in Missouri state court, went through the Missouri Court of Appeals, and drew a jury verdict in Missouri before the Supreme Court reversed it.
In 2018, Bayer AG, the German pharmaceutical and agricultural giant, acquired Monsanto for $63 billion. Monsanto is now a wholly-owned subsidiary of Bayer. The caption defendant in Roundup cases is still “Monsanto Company,” but Bayer bears ultimate financial responsibility for the litigation exposure worldwide. Bayer’s deep pockets — it is one of the largest chemical and pharmaceutical companies on earth — mean the resources to fight these cases are effectively unlimited. Bayer has engaged in broader settlement frameworks for Roundup claims globally, but the Supreme Court’s ruling shifts the settlement calculus. Where Bayer might once have preferred settling claims to avoid trial risk, it now has a powerful new defense weapon that may make litigation cheaper than settlement — at least for failure-to-warn claims.
This is the corporate shell game at work: Monsanto is the named defendant, Bayer is the parent with the balance sheet, and between them sits a web of insurance, indemnity arrangements, and settlement structures that determine where the money actually comes from. Naming the right entity, and understanding the coverage architecture behind it, is foundational work that happens at the start of any case — not after a defense motion reveals you sued the wrong subsidiary.
What Your Case Is Worth After This Ruling
We are going to be honest with you, because honesty is what protects you and dishonesty is what ends a case before it starts.
The $1 million-plus Missouri verdict has been reversed. The failure-to-warn theory that produced it is now largely preempted. For a case built solely on failure to warn — Monsanto should have put a cancer warning on the label — the value has dropped dramatically. The defense will move to dismiss, and the majority’s reasoning gives them a strong argument. A case that was worth $1 million-plus before the ruling may now be worth nothing if failure to warn is the only theory.
For cases with viable alternative theories, the value depends on the evidence. A design defect claim with strong expert testimony that Roundup’s formulation was unreasonably dangerous, supported by internal Monsanto documents showing the company knew of cancer risk, could still support a meaningful recovery. A fraud claim with internal documents showing deliberate suppression of scientific data could support not only compensatory damages but punitive damages. The same injury — non-Hodgkin’s lymphoma from decades of Roundup exposure — carries the same economic and human damages regardless of the legal theory: medical treatment costs that can run into hundreds of thousands of dollars, lost wages, diminished earning capacity, pain and suffering, loss of quality of life, and the emotional toll of a cancer diagnosis.
Severe value deflators: The federal preemption defense is now Supreme Court precedent, not just a trial argument. The EPA’s position that glyphosate is “not likely” to cause cancer is the defense’s strongest factual counter to any cancer-risk-based claim. The Court’s endorsement of FIFRA’s uniform-labeling regime gives the defense a framework to argue that even non-label claims are preempted if they implicitly require a label change.
Potential value inflators: Internal Monsanto or Bayer corporate documents showing knowledge of cancer risk independent of labeling — pre-IARC risk assessments, alleged ghostwriting of scientific literature, post-2015 corporate conduct — can support design defect, negligence, fraud, and punitive damages theories without triggering FIFRA preemption. Missouri’s punitive damages standard — “complete indifference to or conscious disregard for the safety of others” — is a meaningful standard that internal documents showing corporate knowledge of cancer risk could potentially satisfy.
Missouri’s comparative fault rule helps. Missouri follows pure comparative fault, which means your recovery is reduced by your percentage of fault but is never barred entirely. Even if the defense argues you were partly responsible for your own exposure — you used Roundup without protective equipment, or you used more than the label recommended — your recovery is reduced, not eliminated. Every percentage point of fault the defense pins on you is money, which is exactly why they fight for it, but the door never closes entirely in Missouri.
The honest range, post-ruling: a failure-to-warn-only case may be worth $0 if the defense succeeds in dismissing it. A case with strong alternative theories, well-pleaded and well-supported, with NHL-level damages against Bayer’s deep pockets, could potentially yield a verdict in the range of the original Missouri award or higher — but the legal headwinds are substantial, and the path is harder now than it was before the ruling. Past results depend on the facts of each case and do not guarantee future outcomes.
Non-Hodgkin’s Lymphoma: The Injury and Its Lifetime Cost
Non-Hodgkin’s lymphoma is a cancer of the lymphatic system — the network of vessels and nodes that carries infection-fighting white blood cells through the body. It begins when lymphocytes, a type of white blood cell, develop genetic mutations that cause them to multiply uncontrollably and fail to die on schedule. The abnormal cells accumulate in lymph nodes, spleen, bone marrow, and other tissues, forming tumors and disrupting the immune system.
The mechanism by which glyphosate exposure is alleged to cause NHL is a central battleground in the litigation. The International Agency for Research on Cancer (IARC) — the cancer research arm of the World Health Organization — classified glyphosate as “probably carcinogenic to humans” (Group 2A) in 2015, citing evidence of genotoxicity, oxidative stress, and epidemiological studies showing elevated NHL risk in highly exposed individuals. The EPA’s position differs: EPA has repeatedly concluded that glyphosate is “not likely” to cause cancer. That scientific disagreement — between the world’s leading cancer research agency and the federal pesticide regulator — is part of what makes these cases so fiercely contested, and it is part of why the Supreme Court’s ruling, which does not decide the science, leaves the underlying question of whether Roundup causes cancer unresolved.
Diagnostics: NHL is diagnosed through lymph node biopsy (excisional or core needle), followed by pathology and immunohistochemistry to determine the subtype. Staging involves PET/CT imaging, bone marrow biopsy, and blood tests. The subtype and stage determine treatment and prognosis. Diffuse large B-cell lymphoma — the most common subtype — is aggressive but often treatable. Follicular lymphoma is slower-growing but typically incurable. Every subtype carries its own treatment protocol, survival curve, and lifetime monitoring burden.
Treatment: Standard first-line treatment for many NHL subtypes is R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) — a five-drug regimen delivered in cycles over several months. Radiation therapy may follow or replace chemotherapy depending on subtype and stage. For relapsed or refractory disease, treatment escalates to high-dose chemotherapy with stem cell transplant, or to CAR-T cell therapy — a process that genetically engineers the patient’s own immune cells to attack the cancer. Each escalation carries higher cost, higher risk, and a harder recovery.
The cost: A single course of R-CHOP chemotherapy can run into the tens of thousands of dollars per cycle. Rituximab alone — the targeted antibody at the heart of the regimen — carries a price tag that can exceed thousands of dollars per infusion. Stem cell transplants push costs into the hundreds of thousands. CAR-T therapy can cost hundreds of thousands to over a million dollars per patient. On top of the medical bills: lost wages during treatment and recovery, diminished earning capacity if fatigue or cognitive effects persist, and the ongoing cost of surveillance imaging and blood work for years — sometimes for life.
The proof problem the defense exploits: NHL has many causes. It is not a signature disease like mesothelioma, which is almost exclusively caused by asbestos. The defense argues that this plaintiff’s NHL was idiopathic — bad luck, not Roundup. The counter is twofold: general causation (expert testimony that glyphosate can cause NHL, supported by the IARC classification and epidemiological literature) and specific causation (expert testimony linking this plaintiff’s exposure duration, frequency, and intensity to their specific diagnosis, through dose reconstruction and differential diagnosis). Both must survive the applicable expert-admissibility standard — in federal court, Daubert; in Missouri state court, the standard Missouri has adopted. Expert retention is time-sensitive, and the pool of qualified experts is finite.
If the NHL was fatal — and some are — the case becomes a wrongful death claim, with its own procedural requirements, beneficiary hierarchy, and damages framework under Missouri law.
The Evidence That Is Dying Right Now — and How to Save It
Every piece of evidence in a Roundup case has a shelf life. Some of it is permanent. Much of it is not. The single most important thing that happens in the first days and weeks after you contact a lawyer is not filing a lawsuit — it is freezing the evidence before it disappears.
1. Medical records (NHL diagnosis, treatment, pathology, prognosis). These are permanent — hospitals and oncology practices retain records for years, and in many cases indefinitely. But they should be collected and organized immediately, while treating physicians are accessible, while the treatment timeline is fresh, and while the pathology reports can be obtained without hunting through archives. Get the biopsy report, the pathology report with subtype classification, the staging workup, every chemotherapy cycle record, every imaging report, and the treating oncologist’s narrative notes.
2. Roundup purchase and use history. This is the evidence that proves your exposure — how long, how often, how much, and under what conditions. Receipts from hardware stores, garden centers, and agricultural supply companies. Work records if you used Roundup professionally. Agricultural application logs. Witness statements from family members, coworkers, or neighbors who saw you use the product. This evidence deteriorates: businesses close, records are destroyed under retention policies, witnesses relocate or pass away. A receipt from 1998 may not exist in 2026. A coworker who remembers you spraying Roundup every weekend may not be alive in 2030. Document the exposure history now, in detail, with dates, locations, products, frequency, and duration.
3. Internal Monsanto and Bayer corporate documents. This is the evidence that supports the surviving theories — design defect, negligence, fraud, punitive damages. Internal risk assessments conducted before IARC’s 2015 classification. Communications about the IARC response. Documents relating to scientific publication strategies, including any alleged ghostwriting or influence on the scientific literature. Post-2015 corporate conduct reflecting knowledge of cancer risk concerns. These documents are subject to corporate document retention policies and potential destruction. They are not yours to preserve — they are Monsanto’s and Bayer’s. The only way to freeze them is through a litigation-hold letter and aggressive discovery. The preservation demand goes out the day you hire a lawyer, not after a complaint is filed.
4. EPA registration files and label approval correspondence. These are public records — the EPA’s registration files for glyphosate, the label approval correspondence, agency communications regarding glyphosate’s cancer classification. They are voluminous and must be catalogued and analyzed to identify any arguments that support a “parallel claim” theory — the argument, drawn from the dissent, that EPA registration is not conclusive proof that a label complies with all applicable federal requirements. These records do not disappear, but they are complex and require expert analysis to use effectively.
5. Expert causation reports. Both general causation (glyphosate can cause NHL) and specific causation (this exposure caused this plaintiff’s NHL) must be established through qualified expert testimony. Experts must be retained, records must be reviewed, reports must be drafted, and the opinions must survive the applicable admissibility standard. The pool of qualified toxicologists, epidemiologists, and oncologists with the credentials to testify on glyphosate causation is finite, and the litigation volume has placed demands on that pool. Expert retention is time-sensitive.
The preservation letter — the document that orders Monsanto, Bayer, and any third-party custodian to freeze all relevant evidence — is the first thing a lawyer sends. Not after the complaint. Not after discovery. The day you call. If that letter is not on file, the corporate documents that support your strongest surviving theories can be legally destroyed under the company’s retention policies, and you will never know what was there.
How Bayer Will Use This Ruling Against You — and How to Counter Each Play
The defense has a new weapon, and they will use it. Here are the plays you should expect, and the counter to each.
Play 1: The Preemption Hammer. Bayer’s lawyers will file motions to dismiss in every pending Roundup case, arguing that the Supreme Court’s ruling bars not just failure-to-warn claims but any claim that touches on cancer risk and labeling. They will try to expand the ruling’s reach to cover design defect, negligence, and fraud — arguing that any claim premised on cancer risk necessarily implies that the label should have carried a warning, and is therefore preempted.
Counter: The ruling addressed failure-to-warn specifically. Design defect challenges the product’s formulation, not its label. Fraud challenges the company’s scientific conduct, not its label. Plead these theories distinctly and separately from labeling claims, with facts that support each theory independently. The defense’s argument that every cancer-risk claim is really a labeling claim is an expansion of the ruling, not the ruling itself — and it is the fight that will define the next phase of the litigation.
Play 2: The EPA Shield. Bayer will emphasize EPA’s “not likely carcinogenic” position at every stage — in motions, in discovery, at trial. They will argue that the federal regulator’s scientific determination should govern, that any claim premised on cancer risk is contradicted by the EPA’s own assessment, and that a jury should not be allowed to second-guess the EPA’s science.
Counter: The ruling itself says it “does not decide whether Roundup causes cancer.” IARC — the world’s leading cancer research agency — classified glyphosate as “probably carcinogenic” in 2015. The jury in the Missouri case found for the plaintiff despite the EPA’s position. EPA’s scientific determination is evidence the defense will use, but it is not binding on a jury’s factual findings, and it does not preclude contrary scientific evidence. The tension between IARC and EPA is part of the case, not the end of it.
Play 3: The Settlement Squeeze. With preemption as leverage, Bayer’s settlement calculus shifts. Where they might once have offered meaningful sums to resolve failure-to-warn claims, they may now offer less — or refuse to settle failure-to-warn-only claims at all, preferring to litigate the preemption defense. Cases that previously had settlement value may find that value reduced or eliminated.
Counter: Cases with strong non-label theories — design defect supported by internal documents, fraud supported by evidence of scientific suppression, punitive damages supported by corporate knowledge — maintain settlement value because they present trial risk that preemption does not eliminate. The key is building a case the defense cannot simply motion away. A well-pleaded design defect claim with strong expert support and damning internal documents is a case Bayer still has to take seriously.
Play 4: The Theory-Attack. Bayer will argue that design defect claims are failure-to-warn claims in disguise — that any challenge to Roundup’s safety necessarily requires a warning, and is therefore preempted. They will move to dismiss design defect claims on the same preemption grounds.
Counter: Design defect and failure to warn are distinct theories under Missouri law and under the Restatement framework Missouri courts have historically applied. A design defect claim says the product was unreasonably dangerous by formulation; the remedy is changing or removing the product, not adding a label. The Supreme Court’s preemption analysis — which turns on the specific mechanism of a state labeling requirement conflicting with an EPA-approved label — does not automatically extend to a claim that challenges the product itself. This is the legal fight, and it is winnable.
Play 5: The Discovery Stall. Bayer will resist producing internal corporate documents, arguing that any claim requiring those documents is preempted and therefore discovery is irrelevant. They will seek to limit or block discovery into pre-IARC risk assessments, scientific publication strategies, and internal communications about glyphosate’s cancer risk.
Counter: Fraud and negligence claims require discovery of internal corporate documents. Preemption of failure-to-warn does not preclude discovery relevant to non-label theories. The preservation letter and discovery demands must specifically target non-label evidence — corporate knowledge, scientific conduct, marketing practices — and must be pursued aggressively before the documents are lost to retention policies.
How a Surviving Roundup Case Is Actually Built
Here is the chronological walk — what actually happens, week by week, when a Roundup case is built to survive the post-ruling landscape.
Week one: Triage and preservation. The first conversation is not about filing a lawsuit. It is about separating the preempted theories from the potentially surviving ones. Do you have a pure failure-to-warn case, or do you have facts that support design defect, negligence, or fraud? The preservation letter goes out the same week — to Monsanto, to Bayer, to any third-party custodian of relevant evidence — ordering them to freeze internal documents, corporate communications, scientific records, and all materials relating to glyphosate cancer risk research.
Weeks two through four: Evidence collection. Medical records are pulled and organized — the biopsy report, the pathology with subtype, the staging workup, every treatment cycle, every imaging report, every oncologist note. Exposure history is documented in detail — when you used Roundup, where, how often, what products, for how many years, under what conditions. Receipts, work records, agricultural logs, witness statements. The EPA registration file is catalogued. Expert causation analysis begins — identifying the toxicologists, epidemiologists, and oncologists who can testify to general and specific causation.
Months one through three: Pleading and filing. The complaint is drafted with care. Failure-to-warn claims are either omitted or plead narrowly. Design defect, negligence, and fraud claims are pleaded with specific factual allegations drawn from public information about Monsanto’s internal conduct — the IARC response, the alleged scientific publication strategies, the post-2015 corporate behavior. The complaint is built to survive a preemption motion from day one.
Months three through twelve: Discovery. Discovery targets the internal documents that support non-label theories. Interrogatories, document requests, and depositions focus on what Monsanto knew about glyphosate’s cancer risk, when it knew it, what it did with that knowledge, and whether it suppressed or manipulated scientific data. The defense will resist. Motions to compel may be necessary. The documents that emerge — or the documents that are “missing” — become the spine of the case.
Year one and beyond: Experts, motions, and trial preparation. Expert reports are prepared on design defect (was the formulation unreasonably dangerous?), specific causation (did this exposure cause this cancer?), and damages (what is the lifetime cost of this injury?). Daubert motions may be filed by either side. The defense will file summary judgment motions arguing preemption extends to all claims. The plaintiff will oppose, arguing the ruling was limited to failure-to-warn. If the case survives, it moves toward trial — where a Missouri jury, not an EPA bureaucrat, decides whether the evidence supports accountability.
What to Do in the First 72 Hours
1. Get your medical records together. Your NHL diagnosis, your pathology report, your treatment records, your imaging reports, your oncologist’s notes. If you do not have copies, request them from every treating facility — hospitals, oncology practices, imaging centers. These are your permanent records, but getting them organized now — while the timeline is fresh and the providers are accessible — saves weeks later.
2. Document your Roundup use in writing. Write down everything you can remember: what products you used (Roundup concentrate, Roundup ready-to-use, Roundup Pro, generic glyphosate), where you bought them, how often you used them (weekly, monthly, seasonally), how many years you used them, what you were doing when you used them (residential lawn care, commercial landscaping, agriculture, maintenance work), whether you wore protective equipment, and whether you mixed or sprayed the product. Include approximate dates, locations, and quantities. This document — your personal exposure history — is the foundation of your specific causation case, and memory fades.
3. Do not sign anything from Monsanto, Bayer, or any insurance company. No release, no settlement agreement, no authorization for medical records, no statement of any kind. If someone has sent you a document, read it carefully and do not return it until a lawyer has reviewed it.
4. Do not give a recorded statement to anyone. Not to Monsanto’s claims department, not to an insurance adjuster, not to an investigator, not to a “researcher” calling about Roundup. Anything you say can and will be used to minimize or deny your claim. The friendly voice on the phone is not your friend.
5. Do not post about your case on social media. No Facebook posts about your diagnosis. No Twitter threads about Roundup. No Instagram photos of chemotherapy. The defense monitors social media, and a photo of you smiling at a family event during treatment can become Exhibit A in an argument that your suffering is not as severe as you claim.
6. Call a lawyer who understands the post-ruling landscape. Not just any lawyer — one who has read the Supreme Court’s ruling, understands the difference between a preempted failure-to-warn claim and a potentially surviving design defect claim, and knows how to build a case around internal corporate documents rather than label warnings. The consultation is free. The call is 1-888-ATTY-911. We work with local counsel in Missouri where required, and we handle toxic tort and product liability cases at the level these cases demand.
Why the Dissent Matters — Justice Jackson’s Parallel-Claim Framework
Justice Ketanji Brown Jackson dissented, joined by Justice Neil Gorsuch. The dissent is not law — the majority’s holding controls. But the dissent matters for three reasons, and understanding it is part of understanding what your case can become.
First, the dissent laid out a framework for “parallel claims” that could inform future state-court analysis of surviving theories. Jackson argued that Durnell’s claim did not add a new requirement because federal law itself bars “misbranded” pesticides — including pesticides with labels that lack warnings needed to protect health and the environment. Under this view, Missouri’s failure-to-warn claim was parallel to FIFRA’s own misbranding prohibition, not different from it. EPA’s registration of a pesticide, Jackson argued, is not conclusive proof that a label complies with every applicable federal requirement. The majority, she wrote, gave EPA label approval more preemptive force than FIFRA actually allows.
Second, the dissent highlighted the “no remedy” problem. The ruling leaves the Missouri plaintiff without a remedy for the harm he alleged — even though a jury agreed with his warning claim. A person who used a product for 20 years, developed cancer, and convinced a jury that the company should have warned him now has nothing, because the Supreme Court says the federal labeling regime prevents the state from requiring that warning. That “no remedy” gap is both a human reality and a political argument — one that may motivate legislative action to amend FIFRA or create a statutory remedy for pesticide injuries that the current preemption regime forecloses.
Third, the dissent is a roadmap. If the Court’s composition changes, if Congress amends FIFRA, or if state courts adopt the parallel-claim reasoning for analyzing surviving theories, the dissent’s framework could become the foundation for a new wave of claims. Justice Thomas, in a separate concurrence, raised broader constitutional concerns about FIFRA’s scope and the federal regulatory power it delegates — concerns that, if pursued in future cases, could reshape the preemption analysis from a different direction.
The generalist reads the headline — “Supreme Court blocks Roundup claim” — and moves on. The lawyer who reads the dissent sees the architecture of the next fight.
Frequently Asked Questions
Can I still file a Roundup cancer lawsuit after the Supreme Court ruling?
Yes, but the path is narrower. The ruling bars failure-to-warn claims that seek a cancer warning different from the EPA-approved label. Claims based on design defect (the product’s formulation was unreasonably dangerous), negligence (the company’s conduct was unreasonable), or fraud (the company suppressed or manipulated scientific data) were not directly addressed and may survive. Whether your specific case is viable depends on your facts, your evidence, and how your lawyer structures the claims.
Does the Supreme Court ruling mean Roundup is safe?
No. The Court said explicitly that its ruling “does not decide whether Roundup causes cancer.” It answered a legal question about preemption — whether federal pesticide law overrides state tort claims seeking a different label warning. The scientific question of whether glyphosate causes non-Hodgkin’s lymphoma remains contested. IARC classified glyphosate as “probably carcinogenic” in 2015. The EPA has concluded it is “not likely” to cause cancer. That disagreement is unresolved.
I already have a Roundup lawsuit filed — what happens to my case?
If your case is based solely on failure to warn, the defense will likely file a motion to dismiss or for summary judgment arguing that your claim is FIFRA-preempted under the Supreme Court’s ruling. If your case includes design defect, negligence, or fraud claims, those claims may survive — but the defense will argue they are preempted too. Your lawyer should be evaluating your case immediately to determine which theories can survive and whether amendment of the complaint is necessary to plead non-label claims with sufficient specificity.
What is FIFRA preemption and why does it matter for my case?
FIFRA is the federal law that governs pesticide registration and labeling. It includes a provision barring states from imposing pesticide labeling requirements that are “in addition to or different from” federal requirements. The Supreme Court held that a state-law failure-to-warn verdict functions as a state labeling requirement — and because the EPA approved Roundup’s label without a cancer warning, a state tort claim seeking that warning conflicts with FIFRA’s uniform-labeling rule. This matters because it eliminates the most common theory Roundup plaintiffs have used to hold Monsanto accountable.
Can I sue Monsanto for design defect instead of failure to warn?
Potentially, yes. A design defect claim challenges the product’s formulation itself — arguing it was unreasonably dangerous by design — rather than the label. The remedy for a design defect is changing or removing the product, not adding a warning. The Supreme Court’s preemption analysis, which turns on the conflict between a state labeling requirement and the EPA-approved label, does not directly address a claim that challenges the product rather than the label. The defense will argue that any cancer-risk-based claim is really a labeling claim in disguise, and that fight is the next frontier of Roundup litigation.
How long do I have to file a Roundup lawsuit in Missouri?
Missouri’s personal injury statute of limitations is five years, under Missouri’s statute of limitations for personal injury actions. For toxic exposure cases like Roundup, the question of when the clock starts — the “accrual” date — can be complex. Many jurisdictions apply a discovery rule for latent diseases, meaning the clock may not start until you knew or reasonably should have known that your injury was connected to the exposure. If you were diagnosed with NHL years after you stopped using Roundup, the accrual date may be the date of diagnosis or the date you learned of the connection — not the date you used the product. This is a state-specific question that depends on your exact facts, and it should be analyzed by a lawyer immediately. Waiting is the single most common way a valid case becomes a dead one.
Does the EPA’s position that glyphosate doesn’t cause cancer kill my case?
No, but it makes the case harder. EPA’s “not likely carcinogenic” determination is evidence the defense will use aggressively. But it is not binding on a jury, and the Supreme Court’s ruling did not adopt the EPA’s science as settled law. IARC’s contrary classification — “probably carcinogenic” — is also evidence. The jury in the Missouri case found for the plaintiff despite the EPA’s position. Your case will need strong expert testimony on both general causation (glyphosate can cause NHL) and specific causation (your exposure caused your NHL), and your lawyer must be prepared to counter the EPA-position argument head-on.
What if I was partly at fault for my Roundup exposure?
In Missouri, you can still recover. Missouri follows pure comparative fault, which means your recovery is reduced by your percentage of fault but is never barred entirely. If a jury finds you 30 percent at fault — say, for not wearing protective equipment — your recovery is reduced by 30 percent. You still recover the remaining 70 percent. This is more favorable than the rule in many states, where being more than 50 percent or 51 percent at fault bars recovery entirely. The defense will work hard to pin percentage points on you, because every point is money — but the door never closes in Missouri.
Can I still get punitive damages in a Roundup case?
Potentially, yes — if the evidence supports it and the claim is not preempted. Missouri permits punitive damages upon a showing of “complete indifference to or conscious disregard for the safety of others.” Internal Monsanto or Bayer corporate documents showing knowledge of cancer risk and deliberate failure to act on that knowledge could potentially meet this standard. The preemption ruling does not bar punitive damages as a category — it bars failure-to-warn claims. If a design defect, negligence, or fraud claim survives and is supported by evidence of conscious disregard, punitive damages may be available on those surviving claims.
What evidence do I need for a Roundup cancer case?
You need four categories of evidence: (1) medical records documenting your NHL diagnosis, subtype, staging, treatment, and prognosis; (2) exposure history showing your Roundup use — products, duration, frequency, intensity, and conditions; (3) expert testimony on general causation (glyphosate can cause NHL) and specific causation (your exposure caused your NHL); and (4) internal corporate documents supporting non-label theories — what Monsanto knew about cancer risk, when it knew it, and what it did with that knowledge. The first two are yours to gather. The third requires expert retention. The fourth requires a preservation letter and discovery.
Why This Firm — and What the First Call Costs
Ralph Manginello is our Managing Partner — 27-plus years in courtrooms, including federal court, a journalist before he was a lawyer, a competitor who does not accept losing. He built this firm to be the place a person in crisis can call at any hour and reach a trial attorney, not an answering service. Ralph has spent his career taking on corporate defendants and insurance companies, and he brings the same intensity to every case — whether it is a refinery explosion, a trucking wrongful death, or a toxic tort that took twenty years to become cancer.
Lupe Peña is our associate attorney — a former insurance-defense attorney who spent years inside a national defense firm, in the rooms where adjusters and their software decided how to deny, delay, and devalue people exactly like you. He knows how the other side values claims, how they select IME doctors, how they run surveillance, and how they use delay tactics — because he used to do it. Now he uses that knowledge for injured clients. Lupe is fluent in Spanish and conducts full consultations in Spanish without an interpreter.
We take Missouri cases, working with local counsel and pro hac vice admission where required. We do not claim an office in Missouri, and we do not pretend to something we are not. What we are is a trial firm with the resources, the experience, and the willingness to take on Bayer — one of the largest chemical companies on earth — in a case that the Supreme Court has made harder but not impossible.
The fee is contingency. Thirty-three and a third percent before trial. Forty percent if the case goes to trial. We do not get paid unless we win your case. The consultation is free. The call is free. The number is 1-888-ATTY-911 (1-888-288-9911). We answer 24 hours a day, seven days a week — live staff, not a machine.
Hablamos Español. Lupe conducts full consultations in Spanish. If your family speaks Spanish at the kitchen table, we speak your language in the courtroom.
This page is legal information, not legal advice. Every case turns on its own facts. Past results depend on the facts of each case and do not guarantee future outcomes. The Supreme Court’s ruling has changed the legal landscape for Roundup cases nationwide, and anyone with a pending or prospective claim needs individualized analysis from a lawyer who has read the ruling and understands which theories survive. That analysis is what we offer, at no cost, on the first call.
The evidence is dying. The clock is running. The ruling has made the path harder but has not closed every door. What happens next depends on what you do today. Call 1-888-ATTY-911.